How much funding has Rapport Therapeutics raised?

Rapport Therapeutics has raised $250.0M in total funding, most recently a Series B round.

Who are Rapport Therapeutics's investors?

Rapport Therapeutics's investors include Cormorant Asset Management, Third Rock Ventures, Johnson & Johnson Innovation, Goldman Sachs, Logos Capital, Fidelity Management.

When was Rapport Therapeutics founded?

Rapport Therapeutics was founded in 2022.

Where is Rapport Therapeutics headquartered?

Rapport Therapeutics is headquartered in Boston, Massachusetts, United States.

What industry is Rapport Therapeutics in?

Rapport Therapeutics operates in Biotech, Healthcare.

How many employees does Rapport Therapeutics have?

Rapport Therapeutics has 11-50 employees.

Rapport Therapeutics

IPO

Public · Boston, United States · Founded 2022 · $250.0M raised

Biotech

Healthcare

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2022
Business Model: B2B
Website: rapportrx.com

Total Funding: $250.0M
Last Round: $150.0M Series BAug 2023
Rounds: 2
Type: Public

About

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts. The company is pioneering a precision medicine approach to neuroscience through its proprietary RAP (Receptor-Associated Protein) technology platform, which enables neuroanatomically precise targeting of GABA-A receptor subtypes. Rapport completed its IPO on Nasdaq (ticker: RAPP) in July 2024.

Summary

Rapport Therapeutics is a Biotech company based in Boston, United States, founded in 2022. It has raised $250.0M in total across 2 rounds, most recently a $150.0M Series B round in Aug 2023. Investors include Cormorant Asset Management, Third Rock Ventures and Johnson & Johnson Innovation.